704 related articles for article (PubMed ID: 19746571)
1. Rosuvastatin for cardiovascular prevention: too many uncertainties.
Prescrire Int; 2009 Aug; 18(102):176. PubMed ID: 19746571
[TBL] [Abstract][Full Text] [Related]
2. Rosuvastatin and primary cardiovascular prevention. Continue to use pravastatin or simvastatin.
Prescrire Int; 2011 Apr; 20(115):94. PubMed ID: 21648210
[No Abstract] [Full Text] [Related]
3. The Jupiter study, CRP screening, and aggressive statin therapy-implications for the primary prevention of cardiovascular disease.
Kones R
Ther Adv Cardiovasc Dis; 2009 Aug; 3(4):309-15. PubMed ID: 19460829
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial.
Brown WV; Bays HE; Hassman DR; McKenney J; Chitra R; Hutchinson H; Miller E;
Am Heart J; 2002 Dec; 144(6):1036-43. PubMed ID: 12486428
[TBL] [Abstract][Full Text] [Related]
5. Rosuvastatin: new preparation. Opt for statins with evidence of efficacy on clinical outcome.
Prescrire Int; 2004 Aug; 13(72):132-4. PubMed ID: 15532136
[TBL] [Abstract][Full Text] [Related]
6. Rosuvastatin in patients with elevated C-reactive protein.
Mak KH; Chan ES
N Engl J Med; 2009 Mar; 360(10):1039-40; author reply 1041-2. PubMed ID: 19271274
[No Abstract] [Full Text] [Related]
7. [The AURORA study].
Pietanza SC; Schena FP; Vassanelli C
G Ital Cardiol (Rome); 2010 Jun; 11(6):449-52. PubMed ID: 20922869
[No Abstract] [Full Text] [Related]
8. Study stirs debate about statin use in those without high cholesterol.
Mayo Clin Womens Healthsource; 2009 Apr; 13(4):3. PubMed ID: 19255535
[No Abstract] [Full Text] [Related]
9. Primary prevention of vascular events in patients with high levels of C-reactive protein: the JUPITER study.
Fonseca FA; Izar MC
Expert Rev Cardiovasc Ther; 2009 Sep; 7(9):1041-56. PubMed ID: 19764857
[TBL] [Abstract][Full Text] [Related]
10. Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study.
Farnier M; Averna M; Missault L; Vaverkova H; Viigimaa M; Massaad R; Vandormael K; Johnson-Levonas AO; Brudi P
Int J Clin Pract; 2009 Apr; 63(4):547-59. PubMed ID: 19222610
[TBL] [Abstract][Full Text] [Related]
11. Low-risk older patients (50 years and older) with raised high-sensitivity CRP (hs-CRP) benefit from rosuvastatin therapy: the JUPITER study.
Cardiovasc J Afr; 2008; 19(6):332-4, discussion 335. PubMed ID: 19104734
[No Abstract] [Full Text] [Related]
12. Comparison of incidences of cardiovascular events among new users of different statins: a retrospective observational cohort study.
Heintjes EM; Penning-van Beest FJ; Johansson S; Stalenhoef AF; Herings RM
Curr Med Res Opin; 2009 Nov; 25(11):2621-9. PubMed ID: 19743959
[TBL] [Abstract][Full Text] [Related]
13. [Lipid lowering by rosuvastatin: how do statins differ?].
Laufs U
Dtsch Med Wochenschr; 2015 Mar; 140(5):313. PubMed ID: 25734669
[No Abstract] [Full Text] [Related]
14. Ezetimibe/simvastatin single tablet versus rosuvastatin in patients with hypercholesterolemia.
Daskalopoulou SS; Mikhailidis DP
Curr Med Res Opin; 2006 Oct; 22(10):2037-9. PubMed ID: 17022863
[TBL] [Abstract][Full Text] [Related]
15. [Statin cuts cardiovascular risk in half].
Einecke D
MMW Fortschr Med; 2008 Dec; 150(49-50):12-3. PubMed ID: 19133364
[No Abstract] [Full Text] [Related]
16. An update on the benefits and risks of rosuvastatin therapy.
Toth PP
Postgrad Med; 2014 Mar; 126(2):7-17. PubMed ID: 24685964
[TBL] [Abstract][Full Text] [Related]
17. Cholesterol lowering, cardiovascular diseases, and the rosuvastatin-JUPITER controversy: a critical reappraisal.
de Lorgeril M; Salen P; Abramson J; Dodin S; Hamazaki T; Kostucki W; Okuyama H; Pavy B; Rabaeus M
Arch Intern Med; 2010 Jun; 170(12):1032-6. PubMed ID: 20585068
[TBL] [Abstract][Full Text] [Related]
18. Quantitative and qualitative effects of rosuvastatin on LDL-cholesterol: what is the clinical significance?
Rizzo M; Berneis K; Spinas GA; Rini GB; Kapur NK
Int J Clin Pract; 2009 Mar; 63(3):478-85. PubMed ID: 19222633
[TBL] [Abstract][Full Text] [Related]
19. Race, ethnicity, and the efficacy of rosuvastatin in primary prevention: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial.
Albert MA; Glynn RJ; Fonseca FA; Lorenzatti AJ; Ferdinand KC; MacFadyen JG; Ridker PM
Am Heart J; 2011 Jul; 162(1):106-14.e2. PubMed ID: 21742096
[TBL] [Abstract][Full Text] [Related]
20. [Comment from the cardiologic viewpoint].
Lüscher TF
Praxis (Bern 1994); 2009 Feb; 98(3):129-30. PubMed ID: 19180438
[No Abstract] [Full Text] [Related]
[Next] [New Search]
